639 results on '"Hanefeld, Markolf"'
Search Results
2. Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial
3. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial
4. Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update
5. Praxis der Therapie des Typ-II-Diabetes: Pathophysiologische Grundlagen, Metabolisches Syndrom, Differentialtherapie, Komplikationen
6. The anorexigenic peptide neurotensin relates to insulin sensitivity in obese patients after BPD or RYGB metabolic surgery
7. Treatment: Alpha Glucosidase Inhibitors
8. Correction to: Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
9. Intravenous Ferric Carboxymaltose in Patients with Type 2 Diabetes Mellitus and Iron Deficiency: CLEVER Trial Study Design and Protocol
10. The Metabolic Syndrome and Cancer
11. Decreasing Postprandial Plasma Glucose Using an α-Glucosidase Inhibitor in Subjects with IGT for the Prevention of Type 2 Diabetes Mellitus: The STOP-NIDDM Trial
12. Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in Type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)
13. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide
14. A review of glucagon‐like peptide‐1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus
15. Efficacy and safety of lixisenatide in patients with type 2 diabetes and renal impairment
16. The Role of Alpha-Glucosidase Inhibitors (Acarbose)
17. Early Treatment with Basal Insulin Glargine in People with Type 2 Diabetes: Lessons from ORIGIN and Other Cardiovascular Trials
18. The metabolic vascular syndrome - guide to an individualized treatment
19. Determinants of mortality in patients with type 2 diabetes: a review
20. Hypoglycemia and Cardiovascular Disease: Lessons from Outcome Studies
21. Risk of and risk factors for hypoglycemia and associated arrhythmias in patients with type 2 diabetes and cardiovascular disease: a cohort study under real-world conditions
22. A Practical Guide to the Therapy of Type-II-Diabetes
23. Störungen des Lipid- und Lipoproteinstoffwechsels
24. Lixisenatide Treatment for Older Patients with Type 2 Diabetes Mellitus Uncontrolled on Oral Antidiabetics: Meta-Analysis of Five Randomized Controlled Trials
25. Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial
26. Clinical features and treatment of coronary heart disease in diabetes
27. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
28. Insulin Use Early in the Course of Type 2 Diabetes Mellitus: The ORIGIN Trial
29. Zum Beitrag: „Testosteronmangel im Alter – was ist zu tun“
30. Multimodale Therapie von Fettstoffwechselstörungen
31. The Effect of Darapladib on Plasma Lipoprotein-Associated Phospholipase A2 Activity and Cardiovascular Biomarkers in Patients With Stable Coronary Heart Disease or Coronary Heart Disease Risk Equivalent: The Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Study
32. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias
33. A new HPLC-based assay for the measurement of fructosamine-3-kinase (FN3K) and FN3K-related protein activity in human erythrocytes
34. Efficacy and Safety of Coadministration of Fenofibrate and Ezetimibe Compared with Each as Monotherapy in Patients with Type IIb Dyslipidemia and Features of the Metabolic Syndrome: A Prospective, Randomized, Double-Blind, Three-Parallel Arm, Multicenter, Comparative Study
35. Effect of Acarbose on Vascular Disease in Patients with Abnormal Glucose Tolerance
36. The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
37. An exploratory analysis of the REWIND trial
38. Das metabolische Syndrom: „common soil“ für Diabetes und Atherosklerose: Neue Möglichkeiten für eine integrierte Therapie
39. Rosiglitazone evaluated for cardio-vascular outcomes - An interim analysis
40. Anti-Inflammatory Effects of Pioglitazone and/or Simvastatin in High Cardiovascular Risk Patients With Elevated High Sensitivity C-Reactive Protein: The PIOSTAT Study
41. Effect of simvastatin and/or pioglitazone on insulin resistance, insulin secretion, adiponectin, and proinsulin levels in nondiabetic patients at cardiovascular risk—the PIOSTAT Study
42. Postprandiale Hyperglykämie als Risikofaktor bei Herz-Kreislauf-Erkrankungen: Therapie verbessert Prognose
43. Effect of Insulin Glargine and n-3FA on Carotid Intima-Media Thickness in People With Dysglycemia at High Risk for Cardiovascular Events: The Glucose Reduction and Atherosclerosis Continuing Evaluation Study (ORIGIN-GRACE)
44. GW24-e3085 The dual PPAR alpha/gamma agonist aleglitazar has a beneficial effect on atherogenic dyslipidemia in patients with type 2 diabetes
45. Treatments for the Metabolic Syndrome
46. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial
47. Hyperlipidämie und Fibrate unter besonderer Berücksichtigung des Diabetes
48. Should antidiabetic treatment of type 2 diabetes in patients with heart failure differ from that in patients without?
49. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
50. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.